SCHEDULE: Atlas Venture Funds Adjust Dyne Therapeutics Stake

Atlas Venture Fund XI, L.P. and affiliated entities have reported a change in their beneficial ownership of Dyne Therapeutics, Inc. common stock, now holding a combined 3.6% stake.

Summary

• This filing is an amendment to a Schedule 13G, reporting changes in beneficial ownership of Dyne Therapeutics, Inc. common stock.
• The reporting persons are various Atlas Venture entities, including Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, L.P., and Atlas Venture Associates Opportunity II, LLC.
• Collectively, these entities beneficially own 6,800,099 shares of common stock, representing 3.6% of the outstanding shares.
• The filing details the shared voting and dispositive power for each reporting entity over the shares they hold.
• The date of the event requiring this filing is June 30, 2026, and the statement was signed on August 13, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without new operational or financial performance data.

Positives

• The filing indicates continued investment interest from a significant venture capital firm in Dyne Therapeutics.
• The reporting entities collectively hold a substantial 3.6% stake, suggesting a belief in the company's long-term prospects.

Negatives

• The filing does not provide any new operational or financial performance data for Dyne Therapeutics.
• The reporting entities disclaim group membership, which could imply a lack of coordinated strategy among the Atlas entities regarding their holdings.

Risks

• The filing does not explicitly mention any new risks or challenges for Dyne Therapeutics.
• Potential for future changes in beneficial ownership by these large holders could impact stock price volatility.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Dyne Therapeutics' future performance.

Industry Context

StockSavvy.ai notes that venture capital firms frequently adjust their holdings in publicly traded portfolio companies, especially in the biotechnology sector, as companies mature or approach key development milestones. This filing reflects such a typical portfolio management activity.

Stakeholder Impact

• Shareholders may note the increased or adjusted stake by a significant investor, potentially influencing market perception.
• The filing does not directly impact employees, customers, suppliers, or creditors.

Next Steps

• Continued monitoring of Atlas Venture entities' holdings and any further amendments to Schedule 13G filings.
• Observation of Dyne Therapeutics' operational and clinical development progress.

Key Dates

Keywords

Dyne Therapeutics, Atlas Venture, Schedule 13G, Beneficial Ownership, Venture Capital, Common Stock, Investment Funds